ArticleEuropean journal of clinical pharmacology2025
Impact of CYP2D6 genotype on fluoxetine exposure and treatment switch in adults and children/adolescents.
Article in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Application of Physiologically Based Pharmacokinetic Modeling to Optimize Assessment of Age-Related Fluoxetine Accumulation in the Elderly.CPT: pharmacometrics & systems pharmacology · 2026Article
- Pharmacogenomics ofPharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe relevance of CYP2D6 activity on serum levels and clinical response of fluoxetine remains unclear. The present study aim was to evaluate the impact of CYP2D6 genotype on i) fluoxetine and norfluoxetine exposure, and ii) treatment switch from fluoxetine to alternative antidepressants in adults and children/adolescents.
methodsPatients were included retrospectively from a therapeutic drug monitoring service. Patients were subgrouped by age, i.e. < 18 yrs (young) and ≥ 18 yrs (adult), and divided into CYP2D6 genotype-predicted phenotype subgroups of poor metabolizers (PMs), intermediate metabolizers (IMs), normal metabolizers (NMs) and ultrarapid metabolizers (UMs).
resultsAmong 1027 adult patients, the metabolic ratio was lowest in PMs and highest in UMs (p ≤ 0.04), but there was no difference in active moiety (fluoxetine + norfluoxetine) across CYP2D6 phenotype groups (p ≥ 0.1). Similar trends were observed in 196 young patients, both for metabolic ratio and active moiety. In adult patients, switching from fluoxetine to an alternative antidepressant had odds ratio of 2.9 in UMs (p = 0.004) and 2.3 in PMs (p = 0.007) compared with NMs. The number of switches per genotype group was too low for meaningful comparisons in young patients.
conclusionThe fluoxetine and norfluoxetine active moiety was unaffected by CYP2D6 genotype in adults and children/adolescents. Still, adult CYP2D6 PMs and UMs switched antidepressant treatment two to three times more often than NMs, indicating that relative levels of fluoxetine and norfluoxetine may affect treatment outcome rather than active moiety in relation to CYP2D6 phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.